Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present) [0.03%]
针对靶向LPA1信号通路治疗纤维化的专利综述(2010-至今)
Zhihao Gu,Yong Yan,Hequan Yao et al.
Zhihao Gu et al.
Introduction: Fibrosis is a disease that damages organs and even causes death. Because of the complicated pathogenesis, the development of drugs for fibrosis is challenging. In the lysophosphatidic acid receptor type 1 (L...
Ruijun Tang,Jing Liu,Shuyao Li et al.
Ruijun Tang et al.
Introduction: Cyclin-dependent kinase 12 (CDK12) belongs to the CDK family of serine/threonine protein kinases and is associated with cyclin K to exert its biological functions, including regulating gene transcription, mR...
Stephen J Atkinson,Laura Evans,James S Scott
Stephen J Atkinson
Introduction: In methylthioadenosine phosphorylase (MTAP)-deficient tumor cells, reduced S-adenosylmethionine (SAM) levels in the context of elevated methylthioadenosine (MTA) has been hypothesized to lead to inhibition o...
Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins [0.03%]
针对抗凋亡B细胞淋巴瘤-2家族蛋白的抑制剂和PROTAC专利布局分析
Pratik Pal,Peiyi Zhang,Saikat K Poddar et al.
Pratik Pal et al.
Introduction: The anti-apoptotic BCL-2 family proteins, such as BCL-2, BCL-XL, and MCL-1, are excellent cancer therapeutic targets. The FDA approval of BCL-2 selective inhibitor venetoclax in 2016 validated the strategy o...
A patent review of pharmaceutical and therapeutic applications of oxadiazole derivatives for the treatment of chronic diseases (2013-2021) [0.03%]
2013-2021年噁二唑衍生物在药物和治疗领域的专利分析：慢性病治疗应用
Abbas Hassan,Abid Hussain Khan,Faiza Saleem et al.
Abbas Hassan et al.
Introduction: Oxadiazole is a unique class of heterocycle, possessing numerous important biomedical and therapeutic applications, such as anti-bacterial, anti-cancer, anti-inflammatory, inhibitors for diverse enzymes, rec...
Huanhuan Chen,Zhenling Liu,Lili Zheng et al.
Huanhuan Chen et al.
Introduction: Bromodomain and extraterminal (BET) proteins are epigenetic readers that regulate gene transcription and cell growth by binding to acetylated lysine residues on histones. They are involved in many physiologi...
Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections - structure proposal for Phaeno Therapeutics drug candidate HN0037 [0.03%]
Medshine Discovery公司的解螺旋酶-引物酶抑制剂（WO2018/127207和WO2020/007355）用于治疗单纯疱疹病毒感染-HN0037（Phaeno Therapeutics公司药物候选化合物）结构预测
Christian Gege,Gerald Kleymann
Christian Gege
Helicase-primase is an interesting target for small-molecule therapy of herpes simplex virus (HSV) infections. With amenamevir already approved for varicella-zoster virus and with pritelivir's granted breakthrough therapy designation for th...
Iron oxide nanoparticles for biomedical applications: an updated patent review (2015-2021) [0.03%]
铁氧化纳米颗粒的生物医药应用专利回顾（2015-2021）
Zeyuan Mao,Xin Li,Pengfei Wang et al.
Zeyuan Mao et al.
Introduction: Iron oxide nanoparticles (IONPs) hold the edges of great magnetic properties and fine nanoparticle characteristics, making them an attractive therapeutic agent. In the past seven years, more in-depth investi...
LSD1 inhibitors for anticancer therapy: a patent review (2017-present) [0.03%]
抗癌治疗中的LSD1抑制剂专利回顾（2017-至今）
Yi-Xin Lv,Sheng Tian,Zhou-Dong Zhang et al.
Yi-Xin Lv et al.
Introduction: Lysine-specific demethylase 1 (LSD1), which belongs to the demethylase of non-histone proteins, is believed to promote cancer cell proliferation and metastasis by modifying histones. LSD1 dysfunction may pla...
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present) [0.03%]
YAP/TAZ-Tead抑制剂的研发进展（2018年至今）——专利回顾
Benjamin Zagiel,Patricia Melnyk,Philippe Cotelle
Benjamin Zagiel
Introduction: The Hippo pathway represents a new opportunity for the treatment of cancer. Overexpression of Yes-associated protein (YAP) or transcriptional coactivator with PDZ-binding motif (TAZ) or TEAD has been demonst...